Silencing of the CrkL gene reverses the doxorubicin resistance of K562/ADR cells through regulating PI3K/Akt/MRP1 signaling

BACKGROUND: Doxorubicin is a first‐line chemotherapy agent on human myelogenous leukemia clinical treatment, but the development of chemoresistance has largely limited curative effect. In this study, we aimed to evaluate the biological function and molecular mechanisms of CrkL to Doxorubicin resista...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Jiang, Chen, Wen‐XU, Xie, Wen‐Jing, Chen, Rong‐Wei, Lin, Dan‐Qi, You, Wei‐Wei, Ye, Wei‐Lin, Zhang, Hong‐Qin, Lin, Dong‐Hong, Xu, Jian‐Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373353/
https://www.ncbi.nlm.nih.gov/pubmed/34114685
http://dx.doi.org/10.1002/jcla.23817

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373353/
https://www.ncbi.nlm.nih.gov/pubmed/34114685
http://dx.doi.org/10.1002/jcla.23817

Ejemplares similares